

References

- Abd El-Wahab MF, Zakaria S, Kamel M, et al; (1994).** High seroprevalence of hepatitis C virus infection among risk groups in Egypt. *Am J Trop Med Hyg*; 51(5):563-567.
- Afdhal NH, Dieterich DT, Pockros PJ, et al; (2004).** Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. *Gastroenterology*; 126(5):1302-11.
- Alberti A, Noventa F, Benvegna L, et al; (2002).** Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. *Ann Intern Med*; 137:961-964.
- Alter MJ, Kruszon-Moran D, Nainan OV, et al; (1999).** The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med*; 341:556–62.
- Ansaldi F, Torre F, Bruzzone BM, et al; (2001).** Evaluation of a new hepatitis C virus sequencing assay as a routine method for genotyping. *J Med Virol*; 63:17-21.
- Antonelli A, Ferri C, Pampana A, et al; (2004).** Thyroid disorders in chronic hepatitis C. *Am J Med*; 117:10.
- Arthur RR, Hassan NF, Abdallah MY, et al; (1997).** Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. *Trans. R. Soc. Trop. Med. Hyg*; 91:271-274.

- Attia MA, Abdel-Hadi S, Alam El-Din HM, et al; (1996).** Seroprevalence of hepatitis C amongst Egyptian pediatric acute leukemics and their siblings of N.C.I., Egypt: genotyping and risk of intrafamilial transmission. *Proceedings of the American Society of Clinical Oncology*; 15:370.
- Azzari C, Resti M, Moriondo M, et al; (2000).** Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection. *Blood*; 96:2045.
- Bakker AJ, Mirchi B, Dijkstra JT, et al; (2003).** IFCC method for lactate dehydrogenase measurement in heparin plasma is unreliable [Technical Brief]. *Clin Chem*; 49:662-664.
- Barrera JM, Bruguera M, Ercilla MG, et al; (1995).** Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. *Hepatology*; 21:639.
- Bassily S, Hyam KC, Fouad RA, et al; (1995).** A high risk of hepatitis C infection among Egyptian blood donors: the role of parenteral drug abuse. *Am. J. Trop. Med. and Hyg*; 52:503-505.
- Beddhu S, Bastacky S and Johnson JP. (2002).** The clinical and morphologic spectrum of renal cryoglobulinemia. *Medicine (Baltimore)*; 81:398.
- Bergman S, Accortt N, Turner A, et al; (2005).** Hepatitis C infection is acquired pre-ESRD. *Am J Kidney Dis*; 45:684.

- Bhavsar AR. (2006).** Diabetic retinopathy. the latest in current management. *Retina*; 26(6 Suppl):S71-9.
- Bigam DL, Pennington JJ, Carpentier A, et al; (2000).** Hepatitis C-related cirrhosis: A predictor of diabetes after liver transplantation. *Hepatology*; 32:87.
- Bigby M. (2009).** The relationship between lichen planus and hepatitis C clarified. *Arch Dermatol*; 145(9):1048-50.
- Biggs S, Rosemary AF, et al; (1976).** Human Blood Coagulation, Haemostasis and Thrombosis, 2nd Ed., Blackwell Scientific Publications, London; 9:238-54.
- Bodenheimer H, Lindsay KL, Davis GL, et al; (1997).** Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. *Hepatology*; 26:473.
- Boitieux JL, Desmet G and Thomas D. (1978).** Potentiometric Determination of Hepatitis B Surface Antigen in Biological Fluids, *Clinical Chim Acta*; 88(2): 329 –336.
- Borghi-Scoazec G, Merle P, Scoazec JY, et al; (2004).** Onset of dermatitis herpetiformis after treatment by interferon and ribavirin for chronic hepatitis C. *J Hepatol*; 40:871.
- Bouvier-Alias M, Patel K, Dahari H, et al; (2002).** Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. *Hepatology*; 36:211-218.

- Brau N, Bini EJ, Stancic S, et al; (2003).** Severe migraine headaches are caused by ribavirin but not by interferon alpha-2B in combination therapy for chronic hepatitis C. *J Hepatol*; 38:871.
- Brunt EM. (2000).** Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond. *Hepatology*; 31: 241-246.
- Bulaj ZJ, Phillips JD, Ajioka RS, et al; (2000).** Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. *Blood*; 95:1565.
- Cacoub P, Renou C, Rosenthal E, et al; (2000).** Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. *The GERMIVIC. Medicine (Baltimore)*; 79:47.
- Callas DD, Clark TL, Moreira PL, et al; (1997).** In vitro effects of a novel hemoglobin-based oxygen carrier on routine chemistry, therapeutic drug, coagulation, hematology, and blood bank assays. *Clin Chem*; 43:1744-48.
- Casato M, Agnello V, Pacillo LP, et al; (1997).** Predictors of long term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. *Blood*; 90:386.
- Centers for Disease Control and Prevention. (1998).** Recommendations for prevention and control of Hepatitis C virus (HCV) infection and HCV-related chronic disease. *MMWR*; 47 (rr-19).

- Chambers RB, Downie A, Foote B, et al; (2007).** Interferon alfa associated retinopathy. *J Am Osteopath Assoc*; 97(1):43-45.
- Cheng SJ, Bonis PA, Lau J, et al; (2001).** Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials. *Hepatology*; 33:231.
- Chu CM, Yeh CT and Liaw YF. (1999).** Fulminant hepatic failure in acute hepatitis C: Increased risk in chronic carriers of hepatitis B virus. *Gut*; 45:613.
- Cline D, Hofstetter HW and Griffin JR. (1997).** Dictionary of Visual Science. 4th ed. Butterworth-Heinemann, Boston; ISBN 0-7506-9895-0.
- Cody SH, Nainan OV, Garfein RS, et al; (2002).** Hepatitis C virus transmission from an anesthesiologist to a patient. *Arch Intern Med*; 162:345.
- Colin C, Lanoir D, Touzet S, et al; (2001).** Sensitivity and specificity of thirdgeneration hepatitis C virus antibody detection assays: an analysis of the literature. *J Viral Hepat*; 8:87 95.
- Crotty S, Maag D, Arnold JJ. et al; (2000).** The broadspectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. *Nat Med*; 6:1375.
- Curley SA, Izzo F, Gallipoli A, et al; (1995).** Identification and screening of patients with chronic hepatitis at high risk to develop hepatocellular carcinoma. *Ann Surg*; 222:375-383.

- Cuthbertson FM, Davies M and McKibbin M. (2004).** Is screening for interferon retinopathy in hepatitis C justified? *Br J Ophthalmol*; 88:1518–1520.
- Darwish MA, Raouf TA and Rushdy P. (1993).** Risk factors associated with a high seroprevalence of hepatitis C virus infection in Egyptian blood donors. *Am. J. Trop. Med. Hyg*; 49:440-447.
- Deuffic S, Buffat L, Poynard T, et al; (1999).** Modeling the hepatitis C virus epidemic in France. *Hepatology*; 29:1596–601.
- Diabetic Retinopathy Clinical Research Network. (2008).** A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for macular edema. *Ophthalmology*; 115(9):1447-9.
- Di Bisceglie AM. (2000).** Natural history of hepatitis C: Its impact on clinical management. *Hepatology*; 31:1014-1018.
- Di Bisceglie AM and Hoofnagle JH. (2002).** Optimal therapy of hepatitis C. *Hepatology*; 36:S121-S127.
- Di Martino V, Lebray P, Myers RP, et al; (2004).** Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. *Hepatology*; 40:1426.
- Dixit NM, Layden-Almer JE, Layden TJ, et al; (2004).** Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. *Nature*; 432:922.

- Duly EB, Grimson S, Barnes G, et al; (2003).** Measurement of serum albumin by capillary zone electrophoresis, bromocresol green, bromocresol purple, and immunoassay methods. *J Clin Pathol*; 56:780-781.
- Dusheiko G. (1997).** Side effects of alpha interferon in chronic hepatitis C. *Hepatology*; 26:112S.
- Duvnjak M, Pavic T, Tomasic V, et al; (2005).** Hepatitis C treatment of naive patients. *Acta. Med. Croatica*; 59(5):453-461.
- Duvoux C, Pawlotsky JM, Bastie A, et al; (1999).** Low HCV replication levels in endstage hepatitis C virus-related liver disease. *J Hepatol*; 31:593-597.
- Edlin BR, Seal KH, Lorvick J, et al; (2001).** Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?. *N Engl J Med*; 345:211.
- El-Serag HB, Hampel H, Yeh C, et al; (2002).** Extrahepatic manifestations of hepatitis C among United States male veterans. *Hepatology*; 36:1439.
- El-Serag HB. (2002).** Hepatocellular carcinoma: an epidemiological view. *J Clin Gastroenterol*; 35 (suppl): S72–78.
- Fabris P, Betterle C, Greggio NA, et al; (1998).** Insulindependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. *J Hepatol*; 28:514.

- Farci P, Shimoda A, Coiana A, et al; (2000).** The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. *Science*; 288: 339-344.
- Fattovich G, Giustina G, Degos F, et al; (1997).** Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. *Gastroenterology*; 112:463.
- Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al; (1998).** Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. *Arch Intern Med*; 158:1445.
- Formann E, Stauber R, Denk DM, et al; (2004).** Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. *Am J Gastroenterol*; 99:873.
- Frank C, Mohamed MK, Strickland GT, et al; (2000).** The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet*; 355:887-891.
- French METAVIR Cooperative Study Group. (1994).** Intraobserver and interobserver variations in liver biopsies in patients with chronic hepatitis C. *Hepatology*; 20:15-20.
- Fried MW, Shiffman ML, Reddy KR, et al; (2002).** Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. *New England Journal of medicine*; 347:792-982.
- Fried MW. (2002).** Side-effects of therapy of hepatitis C and their management. *Hepatology*; 36:S237-S244.

- Frons X, Ampurdanes S, Llovet JM, et al; (2002).** Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. *Hepatology*; 36:986-992.
- Garcia-Suarez J, Burgaleta C, Hernanz N, et al; (2000).** HCV-associated thrombocytopenia: Clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. *Br J Haematol*; 110:98.
- Georgetson MJ, Yarze JC, Lalos AT, et al; (1993).** Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. *Am J Gastroenterol*; 88:1756.
- Giannini E, Risso D, Botta F, et al; (2003).** Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. *Arch Intern Med*; 163:218.
- Gisbert JP, Garca-Buey L, Pajares JM, et al; (2003).** Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: Systematic review and metaanalysis. *Gastroenterology*; 125:1723.
- Gordon SC, Fang JW, Silverman AI, et al; (2000).** The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. *Hepatology*; 32:400-404.
- Grakoui A, Hanson HL and Rice CM. (2001).** Bad time for Bonzo? Experimental models of hepatitis C virus infection. Replication and pathogenesis. *Hepatology*; 33:489-495.

- Grakoui A, Shoukry NH, Woollard DJ, et al; (2003).** HCV persistence and immune evasion in the absence of memory T cell help. *Science*; 302:659.
- Gurtubay IG, Morales G, Arechaga O, et al; (1999).** Development of myasthenia gravis after interferon alpha therapy. *Electromyogr Clin Neurophysiol*; 39:75.
- Guyer DR, Tiedeman J, Yannuzzi LA, et al; (1993).** Interferon-associated retinopathy. *Arch Ophthalmol*; 111:350-356.
- Hadziyannis SJ, Sette H, Morgan TR, et al; (2004).** Peginterferon- α 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med*; 140:346-55.
- Haley RW and Fischer RP. (2001).** Commercial tattooing as a potentially important source of hepatitis C infection. *Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine (Baltimore)*; 80:134.
- Halfon P, Levy M, San Marco M, et al; (1996).** Myasthenia gravis and hepatitis C virus infection. *J Viral Hepat*; 3:32.
- Hassanein T, Cooksley G, Sulkowski M, et al; (2004).** The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. *J Hepatol*; 40:675-681.
- Hayasaka S, Fujii M, Yamamoto Y, et al; (1995).** Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. *Br J Ophthalmol*; 79:150–2.

- Hayasaka S, Nagaki Y, Matsumoto M, et al; (1998).** Interferon associated retinopathy. *Br J Ophthalmol*; 82:323-5.
- Heathcote EJ, Shiffman ML, Cooksley WG, et al; (2000).** Pegylated interferon alpha-2a in patients with chronic hepatitis C and cirrhosis. *N Engl J Med*; 343:1673-1680.
- Hermine O, Lefrere F, Bronowicki JP, et al; (2002).** Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. *N Engl J Med*; 347:89.
- Hibbs RG, Corwin AL, Hassan NF, et al; (1993).** The epidemiology of antibody to hepatitis C in Egypt. *J Infect Dis*; 168(3):789-790.
- Hilsabeck RC, Perry W and Hassanein TI. (2002).** Neuropsychological impairment in patients with chronic hepatitis C. *Hepatology*; 35:440.
- Hiram G, Bezerra MD, Marco A, et al; (2009).** "Intracoronary Optical Coherence Tomography: A Comprehensive Review: Clinical and Research Applications". *JACC Cardiovascular Interventions*; 2(11):1035-1046.
- Hofmann WP, Bock H, Weber C, et al; (2006).** Effectiveness of Antiviral Therapy in Patients with Chronic Hepatitis C Treated by Private Practice Gastroenterologists. *Gastroenterol*; 44(1):25-31.
- Homma M, Matsuzaki Y, Inoue Y, et al; (2004).** Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. *Clin Gastroenterol Hepatol*; 2:337.

- Hu KQ and Tong MJ. (1999).** The long-term outcomes of patients with compensated hepatitis C virus- related cirrhosis and history of parenteral exposure in the United States. *Hepatology*; 29:1311.
- Hui JM, Sud A, Farrell GC, et al; (2003).** Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. *Gastroenterology*; 125:1695.
- Ikebe T, Nakatsuka K and Goto M. (1990).** A case of retinopathy induced by intravenous administration of interferon. *Folia Ophthalmol Jpn (Ganka-Kiyo)*; 41:2291-2296.
- Ishak KG, Baptista A, Bianchi L, et al; (1995).** Histological grading and staging of chronic hepatitis. *J Hepatol.*; 22:696-699.
- Jacobsen IM, Ahmed F, Russo MW, et al; (2003).** Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in non-responders to interferon monotherapy or combination therapy and in combination therapy relapsers: final results [Abstract]. *Gastroenterology*; 124:A540.
- Kamel MA, Ghaffar YA, Wasef MA, et al; (1992).** High HCV prevalence in Egyptian blood donors. *Lancet*; 340:427.
- Kang HY, Lim JW and Shin MC. (2009).** Pegylated Interferon Associated Retinopathy in Chronic Hepatitis Patients. *J Korean Ophthalmol Soc*; 50(3):383-389.
- Kaplan M, Gawrieh S, Cotler SJ, et al; (2003).** Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics. *Gastroenterology*; 125:597.

- Kawamoto E, Hara T and Kojima T. (1994).** Central retinal vein occlusion associated with interferon. *J Eye (Atarashii Ganka)*; 11:1135–41.
- Kenny-Walsh E. (1999).** Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. *N Engl J Med*; 340:1228.
- Kertes PJ, Johnson TM, et al; (2007).** Evidence Based Eye Care. Philadelphia, PA: Lippincott Williams & Wilkins; ISBN 0-7817-6964-7.
- Kessel A, Rosner I, Zuckerman E, et al. (2000).** Use of antikeratin antibodies to distinguish between rheumatoid arthritis and polyarthritis associated with hepatitis C infection. *J Rheumatol*; 27:610-2.
- Khosla S, Hassoun AA, Baker BK, et al; (1998).** Insulinlike growth factor system abnormalities in hepatitis C associated osteosclerosis. Potential insights into increasing bone mass in adults. *J Clin Invest*; 101:2165.
- Kim EE and Wyckoff HW. (1991).** "Reaction mechanism of alkaline phosphatase based on crystal structures. Two-metal ion catalysis". *J. Mol. Biol*; 218(2): 449–64.
- Kita H, Moriyama T, Kaneko T, et al; (1995).** A helper T-cell antigen U5 enhances generation of hepatitis C virus-specific cytotoxic T lymphocytes in vitro. *J. Med. Virol*; 45:386.

- Kitay-Cohen Y, Amiel A, Hilzenrat N, et al; (2000).** Bcl-2 rearrangement in patients with chronic hepatitis C associated with essential mixed cryoglobulinemia type II. *Blood*; 96:2910.
- Kramer L, Bauer E, Funk G, et al; (2002).** Subclinical impairment of brain function in chronic hepatitis C infection. *J Hepatol*; 37:349.
- Kuga K, Hasumura S, Nagamori S, et al; (1996).** Intraocular hemorrhage developing during interferon therapy. *Intern Med*; 35:15-18.
- Lam A and Ferrucci S. (2006).** Interferon Retinopathy Associated with Hepatitis C. *Clinical and Refractive Optometry*; 17(8):286-291.
- Lau GK, Davis GL, Wu PC, et al; (1996).** Hepatic expression of hepatitis C virus RNA in chronic hepatitis C: study by in situ reverse-transcription polymerase chain reaction. *Hepatology*; 23:1318.
- Lauer G and Walker BD. (2001).** Hepatitis C virus infection. *N Engl J Med*; 345: 41–52.
- Lee SS, Heathcote EJ, Reddy KR, et al; (2000).** Prognosis factors and early predictability of sustained viral response (SVR) in patients treated with pegylated (40kDa) interferon alfa-2A (PEGASYS™): a new profile. *Hepatology*; 32 (4, pt 2):370A.
- Lefrere JJ, Guiramand S, Lefrere F, et al; (1997).** Full or partial seroreversion in patients infected by hepatitis C virus. *J Infect Dis*; 175:316-322.
- Liang TJ, Rehermann B, Seeff LB, et al; (2000).** Pathogenesis, natural history, treatment, and prevention of hepatitis C. *Ann Intern Med*; 132:296.

- Lienesch D, Morris S, Metzger A, et al; (2005).** Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. *J Rheumatol*; 32:489.
- Lindsay KL, Trepo C, Heintges T, et al; (2001).** Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. *Hepatology*; 34:395-403.
- Lucidarme O, Baleston F, Cadi M, et al; (2003).** Non-invasive detection of liver fibrosis: Is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique? *Ur Radiol*; 13:467-474.
- Madala ND, Naicker S, Singh B, et al; (2003).** The pathogenesis of membranoproliferative glomerulonephritis in KwaZulu-Natal, South Africa is unrelated to hepatitis C virus infection. *Clin Nephrol*; 60:69.
- Manesis EK, Moschos M, Brouzas D, et al; (2007).** Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis. *American Journal of Ophthalmology*; 27:1421-1427.
- Marcellin P. (2004).** Management of Patients with Viral Hepatitis. *Hepatology*; 26:133S-137S.
- Martin-Carbonero L, Benhamou Y, Puoti M, et al; (2004).** Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. *Clin Infect Dis*; 38:128.

- Mathiesen UL, Franzen LE, Aselius H, et al; (2002).** Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transminases. *Dig Liver Dis*; 34:516-522.
- Mathurin P, Moussalli J, Cadranel JF, et al; (1998).** Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. *Hepatology*; 27:868–72.
- Matsumori A, Yutani C, Ikeda Y, et al; (2000).** Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. *Lab Invest*; 80:1137.
- Meltzer D. (2008).** Interferon Retinopathy: A Side Effect from the Treatment of Hepatitis C. *Optometry*; 79:320-321.
- Merimsky O, Chaitchik S, et al; (2004).** Neurotoxicity of interferon-alpha. *Anticancer Drugs, American Journal of Hepatology*; 3(6):567-570.
- Mohamed MK, Hussein MH, Massoud AA, et al; (1996).** Study of risk factors for viral hepatitis C infection among Egyptians applying for work abroad. *J. Egyptian Public Health Assoc*; 71(1, 2): 78-111.
- Monti G, Pioltelli P, Saccardo F, et al; (2005).** Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. *Arch Intern Med*; 165:101.
- Moriya K, Fujie H, Shintani Y, et al; (1998).** The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *Nat Med*; 4:1065.

- Murphy EL, Bryzman SM, Glynn SA, et al; (2000).** Risk Factors for Hepatitis C Virus Infection in United States Blood Donors. *Hepatology*; 31:756.
- Myers RP, Benhamou Y, Imbert-Bismut F, et al; (2003).** Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. *AIDS*; 17:721-725.
- Nadir A, Amin A, Chalisa N, et al; (2000).** Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature. *J Viral Hepat*; 7:466-470.
- Nagao Y, Sata M, Ide T, et al; (1996).** Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C. *Eur J Clin Invest*; 26:1171.
- Nawras A, Alsolaiman MM, Mehboob S, et al; (2002).** Systemic sarcoidosis presenting as a granulomatous tattoo reaction secondary to interferon-alpha treatment for chronic hepatitis C and review of the literature. *Dig Dis Sci*; 47:1627.
- Niederau C, Lange S, Heintges T, et al; (1998).** Prognosis of chronic hepatitis C: Results of a large prospective cohort study. *Hepatology*; 28:1687.
- Nolte FS, Fried MW, Shiffman ML, et al; (2001).** "Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests." *J Clin Microbiol*; 39(11):4005-12.

- Oh S and Afdhal NH. (2001).** Hepatic fibrosis: are any of the serum markers useful? *Curr Gastroenterol Rep*; 3:12-18.
- Okanoue T, Sakamoto S, Itoh Y, et al; (1996).** Side effects of high dose interferon therapy for chronic hepatitis c. *J Hepatol*; 25:283.
- Okuse C, Yotsuyanagi H, Nagase Y, et al; (2006).** Risk factors for retinopathy associated with interferon α -2b and ribavirin combination therapy in patients with chronic hepatitis C. *World J Gastroenterol*; 12(23):3756-3759.
- Omura T, Yoshiyama M, Hayashi T, et al; (2005).** Core protein of hepatitis C virus induces cardiomyopathy. *Circ Res*; 96:148.
- Panetta JD and Gilani N. (2009).** Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection. *J Alimentary Pharmacology & Therapeutics*; 30(6):597-602.
- Parker G, Perry J and Jagger J. (2002).** 1999 percutaneous injury rates. *Adv in Exposure Prevention*; 6:7.
- Patel T and Gores GJ. (1995).** Apoptosis and hepatobiliary disease. *Hepatology*; 21:1725.
- Pawlotsky JM, Bouvier M, Fromont P, et al; (1995).** Hepatitis C virus infection and autoimmune thrombocytopenia purpura. *J Hepatol*; 23:635.
- Pawlotsky JM. (2002).** Molecular diagnosis of viral hepatitis. *Gastroenterology*; 122:1554-1568.

- Peck-Radosavljevic M, Wichlas M, Pidlich J, et al; (1998).** Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. *Hepatology*; 28:1424.
- Penin F, Dubuisson J, Rey FA, et al; (2004).** Structural biology of hepatitis C virus. *Hepatology*; 39:5-19.
- Perlemuter G, Cacoub P, Sbai A, et al; (2003).** Hepatitis C virus infection in systemic lupus erythematosus: a case-control study. *J Rheumatol*; 30:1473-1478.
- Petit JM, Bour JB, Galland-Jos C, et al; (2001).** Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. *J Hepatol*; 35:279.
- Pilli M, Penna A, Zerbini A, et al; (2002).** Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. *Hepatology*; 36:1446.
- Planas R, Balleste B, Antonio Alvarez M, et al; (2004).** Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. *J Hepatol*; 40:823.
- Poynard T, McHutchison J, Goodman Z, et al; (2000).** Is the combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? *Hepatology*; 31:211–18.

- Poynard T, McHutchison J, Manns M, et al; (2002).** Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. *Gastroenterology*; 122:1303.
- Purvin VA. (1995):** Anterior ischemic optic neuropathy secondary to interferon alfa. *Arch Ophthalmol*; 113:1041-1044.
- Pusl T and Beuers U. (2005):** Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. *Clin. Rev. Allergy Immunol*; 28(2): 147-157.
- Ramos-Casals M, Loustaud-Ratti V, De Vita S, et al; (2005):** Sjogren Syndrome Associated With Hepatitis C Virus: A Multicenter Analysis of 137 Cases. *Medicine (Baltimore)*; 84:81.
- Ramos-Casals M, Mana J, Nardi N, et al; (2005):** Sarcoidosis in Patients With Chronic Hepatitis C Virus Infection: Analysis of 68 Cases. *Medicine (Baltimore)*; 84:69.
- Reichard O, Foberg U, Fryden A, et al; (2005).** High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha-2b for 60 weeks. *American Journal of Hepatology*; 19:280-5.
- Rodger AJ, Jolley D, Thompson SC, et al; (1999).** The impact of diagnosis of hepatitis C virus on quality of life. *Hepatology*; 30:1299.

- Ross RS, Viazov SO, Holtzer CD, et al; (2000).** Genotyping of hepatitis C virus isolates using CLIP sequencing. *J Clin Microbiol*; 38:3581-3584.
- Ross RS, Viazov S, Gross T, et al; (2000).** Transmission of the hepatitis C virus from a patient to an anesthesiology assistant . *N Engl J Med*; 343:1851.
- Ryan KE, Maclellan S, Barbara JAJ, et al; (1994).** Follow-up of blood donors positive for antibodies to hepatitis C virus. *BMJ*; 308:696.
- Saadah S, Cammeli G, Carey WD, et al; (2001).** The role of liver biopsy in chronic hepatitis C. *Hepatology*; 33:196- 200.
- Sabry AA, Sobh MA, Irving WL, et al; (2002).** A comprehensive study of the association between hepatitis C virus and glomerulopathy. *Nephrol Dial Transplant*; 17:239.
- Saeed A, AL-Admawi A, AL-Rasheed A, et al; (1991).** HCV infection in Egyptian volunteer blood donors in Riyadh. *Lancet*; 338:454-460.
- Sandres K, Dubois M, Pasquier C, et al; (2000).** Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. *J Virol*; 74:661–668
- Sandres K, Dubois M, Pasquier C, et al; (2001).** Determination of HCV genotype using two antibody assays and genome typing. *Eur J Clin Microbiol Infect Dis*; 20:666-669.
- Sandrin L, Fourquet B, Hasquenoph JM, et al; (2003).** a new noninvasive method for assessment of hepatic fibrosis. *Ultrasound Med Biol*; 29:1705-1713.

- Sarrazin C, Gartner BC, Szmann D, et al; (2006).** “Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5.” *J Clin Microbiol*; 44(3):729-37.
- Savant V and Gillow T. (2003).** Interferon-associated retinopathy. *Eye*; 17:534-536.
- Scheuer PJ. (1991).** Classification of chronic viral hepatitis: A need for reassessment. *J. Hepatol*; 13:372-374.
- Seeff LB. (1998).** The natural history of hepatitis C—a quandary. *Hepatology*; 28:1717-1712.
- Seeff LB, Hollinger FB, Alter HJ, et al; (2001).** Long-term mortality and morbidity of transfusion-associated non-A, non- B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. *Hepatology*; 33:455.
- Sen GC, Lengyel P, et al; (2002).** The interferon system. A bird’s eye view of its biochemistry. *J Biol Chem*; 267(8):5017-5020.
- Shaker JL, Moore BP and Whyte MP. (1999).** Hyperparathyroidism and increased serum IGF-binding protein-2 levels in hepatitis C-associated osteosclerosis. *J Clin Endocrinol Metab*; 84:384.
- Shapiro MF and Greenfield SG. (1987).** The complete blood count and leukocyte differential count. *Ann Intern Med*; 106:65-74.

- Shepherd J, Brodin H, Cave C, et al; (2004).** Peglyated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. *Health Technol. Assess*; 8(39): 1-125.
- Sherlock S and Dooley J. (2002).** Hepatitis C virus. In: *Diseases of the liver and biliary system*. Published by Blackwell Science Ltd. U.K. 11th ed. ch. 18. PP; 305-320.
- Shiffman ML. (2002)** Retreatment of HCV nonresponders with peginterferon and ribavirin: Results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial (abstract). *Hepatology*; 36:295A.
- Shiffman ML, Di Bisceglie AM, Lindsay KL, et al; (2004).** Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. *Gastroenterology*; 126:1015.
- Shimura M, Saito T, Yasuda K, et al; (2005).** Clinical course of macular edema in two cases of interferon-associated retinopathy observed by optical coherence tomography. *Jpn J Ophthalmol*; 49:231–234.
- Simmonds P. (1999).** Viral heterogeneity of the hepatitis C virus. *J Hepatol*; 31:54-60.
- Simmonds P, Bukh J, Combet C, et al; (2005).** Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology*; 42:962-973.

- Simsek H, Savas C, Akkiz H, et al; (1996).** Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. *Dermatology*; 193:65.
- Soza A, Everhart JE, Ghany MG, et al; (2002).** Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. *Hepatology*; 36:1273.
- Spiegel BM, Younossi ZM, Hays RD, et al; (2005).** Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. *Hepatology*; 41:790.
- Strader DB, Wright T, Thomas DL, et al; (2004).** Diagnosis, management, and treatment of hepatitis C. *Hepatology*; 39:1147.
- Stroffolini T, Lorenzoni U, Menniti-Ippolito F, et al; (2001).** Hepatitis C virus infection in spouses: Sexual transmission or common exposure to the same risk factors?. *Am J Gastroenterol*; 96:3138.
- Stuyver L, Rossau and Maertens G. (1996).** Line probe assays for the detection of hepatitis B and C virus genotypes. *Antiviral therapy* 1 (Suppl 1); 53-57.
- Tabor E, Epstein JS, et al; (2002).** NAT screening of blood and plasma donations: Evolution of Transfusion technology and regulatory policy; 42:1230.
- Tadokoro Y, Ohtsuki H, Okano M, et al; (1995).** A case of disc edema during systemic interferon therapy. *Folia Ophthalmol Jpn (Ganka-Kiyo)*; 46:653–6.

- Tapp RJ, Shaw JE, Harper CA, et al; (2003).** "The prevalence of and factors associated with diabetic retinopathy in the Australian population". *Diabetic Care*; 26(6):1731–7.
- Thierry Poynard MD, Vlad Ratziu MD, Yves Benmanov MD, et al; (2000).** *Semin Liver Dis*; 20(1):47-55.
- Thio CL, Nolt KR, Astemborski J, et al; (2000).** Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. *J Clin Microbiol*; 38:575-577.
- Thursz M, Yallop R, Goldin R, et al; (1999).** Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. *Lancet*; 354:2119.
- Tilg H. (1997).** New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. *Gastroenterology*; 112: 1017-1021.
- Tokars JJ, Finelli L, Alter MJ, et al; (2004).** National surveillance of dialysis-associated diseases in the United States, *Semin Dial*; 17:310.
- Tong MJ, El-Farra NS, Reikes AR, et al; (1995).** Clinical outcomes after transfusion-associated hepatitis C. *N Engl J Med*; 332:1463.

- Tong MJ, Schiff E, Jensen DM, et al; (2002).** Preliminary analysis of a phase II study of hepatazyme, a nuclease resistant ribozyme targeting hepatitis C virus (HCV) RNA (abstract). *Hepatology*; 36:360A.
- Tsolakos A, Zalatimo N, et al; (2003).** Hepatitis C: a review of diagnosis, management, and ocular complications from treatment. *Optometry*; 74(8): 517-23.
- Tosti A, Misciali C, Bardazzi F, et al; (1992).** Telogen effluvium due to recombinant interferon alpha-2b. *Dermatology*; 184:124.
- Tovo PA, Pembrey LJ and Newell ML. (2000).** Persistence Rate and Progression of Vertically Acquired Hepatitis C Infection. *J Infect Dis*; 181:419.
- Tsolakos A, Zalatimo N, et al; (2003).** Hepatitis C: a review of diagnosis, management, and ocular complications from treatment. *Optometry*; 74(8): 517-23.
- Tu KL, Bowyer J, Schofield K, et al; (2003).** Severe interferon associated retinopathy. *Br J Ophthalmol*; 87:247–8.
- Uchiyama-Tanaka Y, Mori Y, Kishimoto N, et al; (2004):** Membranous glomerulonephritis associated with hepatitis C virus infection: Case report and literature review. *Clin Nephrol*; 61:144.
- Vandelli C, Renzo F, Romano L, et al; (2004).** Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective followup study. *Am J Gastroenterol*; 99:855.

- Vcev A. (2005):** Treatment the side effects of antiviral therapy. *Acta. Med. Croatica*; 59(5):469-472.
- Villano SA, Vlahov D, Nelson KE, et al; (1999).** Persistence of viremia and the importance of long-term followup after acute hepatitis C infection. *Hepatology*; 29:908.
- Vogt M, Lang T, Frosner G, et al; (1999).** Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood donor screening. *N Engl J*; 341:866.
- Vuillermoz I, Khattab E, Sablon E, et al; (2004).** Genetic variability of hepatitis C virus in chronically interferon- Ribavirin therapy. *J Med Virol*; 74:41-53.
- Wahlefeld AW, Herz G and Bernt E. (1972).** Modification of the Malloy-Evelyn method for a simple, reliable determination of total bilirubin in serum [Abstract]. *Scand J Clin Lab Invest*; 29(Suppl 126):11-2.
- Ware JE, Bayliss MS, Mannocchia M, et al; (1999).** Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. *Hepatology*; 30:550.
- Zarski JP, Mc Hutchison J, Bronowicki JP, et al; (2003).** Rate of natural disease progression in patients with chronic hepatitis C. *J Hepatol*; 38:307.

- Zauli D, Ghetti S, Grassi A, et al; (1997).** Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. *Hepatology*; 25:1105.
- Zdilar D, Franco-Bronson K, Buchler N, et al; (2000).** Hepatitis C, interferon alfa, and depression. *Hepatology*; 31:1207.
- Zeuzem S, Herrmann E, Lee JH, et al; (2001).** Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. *Gastroenterology*; 120:1438-1447.
- Zeuzem S, Diago M, Gane E, et al; (2004).** Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. *Gastroenterology*; 127:1724.
- Zignego AL, Ferri C, Giannelli F, et al; (2002).** Prevalence of bcl-2 Rearrangement in Patients with Hepatitis C Virus- Related Mixed Cryoglobulinemia with or without B-Cell Lymphomas. *Ann Intern Med*; 137:571.